trending Market Intelligence /marketintelligence/en/news-insights/trending/l5j9yhbrozwo7zel7_uufg2 content esgSubNav
In This List

Proteostasis plans common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Proteostasis plans common stock offering

Proteostasis Therapeutics Inc. plans to sell 9 million common shares in an underwritten public offering

The company plans to grant the underwriters an option to buy up to an additional 15%, or 1,350,000 common shares, in the public offering.

Leerink Partners and RBC Capital Markets are acting as joint book-running managers, and H.C. Wainwright & Co. is acting as lead manager for the offering.